FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Pollack Kevin 		2. Issuer Name and Ticker or Trading Symbol

Lightlake Therapeutics Inc. [ LLTP ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      __ X __ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)

445 PARK AVENUE, 9TH FLOOR 		3. Date of Earliest Transaction (MM/DD/YYYY)

12/10/2014
(Street)

NEW YORK, NY 10022
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options   $8.00   (1) 5/1/2013   (2)   A      190000       5/1/2013   (2) 4/30/2023   (2) Common Stock, par value $0.001 per share   190000     (3) 390000   D    
Options   $10.00   5/1/2013   (4)   A      165000       5/1/2013   (4) 4/30/2023   (4) Common Stock, par value $0.001 per share   165000     (3) 555000   D    
Options   $15.00   8/1/2013     A      50000       8/1/2013   7/31/2023   Common Stock, par value $0.001 per share   50000     (3) 605000   D    
Options   $20.00   8/1/2013     A      50000       8/1/2013   7/31/2023   Common Stock, par value $0.001 per share   50000     (3) 655000   D    
Options   $6.00   12/31/2013     A      75000       12/31/2013   12/30/2023   Common Stock, par value $0.001 per share   75000     (3) 730000   D    
Options   $5.00   6/15/2014     A      150000       6/15/2014   (5) 6/14/2024   Common Stock, par value $0.001 per share   150000     (3) 880000   D    
Options   $8.00   6/15/2014     A      200000       6/15/2014   (5) 6/14/2024   Common Stock, par value $0.001 per share   200000     (3) 1080000   D    
Options   $7.25   10/27/2015     A      500000       10/27/2015   (6) 10/26/2025   Common Stock, par value $0.001 per share   500000     (4) 1580000   D    

Explanation of Responses:
( 1)  This Form 4 is a late filing reporting the changes in beneficial ownership of the Reporting Person as of October 29, 2015. This Form 4 was required to be filed within two business days of 12/10/2014, the effective date of the Issuer's Form 8-A registration statement which registered the common stock of the Issuer for the first time under Section 12 of the Exchange Act. The Reporting Person voluntarily filed a Form 3 on December 6, 2012 and a Form 4 on January 3, 2013. In December 2014, the Issuer effected a one-for-one hundred reverse stock split of its common stock (the "1:100 Reverse Stock Split"). Unless otherwise noted, all share amounts and exercise prices listed in this Form 3 been retroactively adjusted for the 1:100 Reverse Stock Split as if such stock splits occurred prior to the issuance of such shares, warrants, or options.
( 2)  50,000 vested on 5/1/2013, 50,000 vested on 11/1/2013, and 90,000 vested on 12/31/2013. All expire 10 years after their respective vesting dates.
( 3)  Cashless options.
( 4)  25,000 vested on 5/1/2013, 25,000 vested on 8/1/2013; 25,000 vested on 11/1/13, and 90,000 vested on 12/31/13. All expire 10 years after their respective vesting dates.
( 5)  These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of the next trial with respect to the opioid overdose reversal treatment; (B) the entrance into a distribution, licensing, royalty, partnership, collaboration, or other significant transaction with respect to the opioid overdose reversal treatment; or (C) the filing of a New Drug Application with the U.S. Food and Drug Administration with respect to the opioid overdose reversal treatment; and (ii) the Expiration Date.
( 6)  These options may only be exercised between the following dates: (i) the first to occur of: (A) the commencement of three trials on or subsequent to October 23, 2015; or (B) (1) the approval by the U.S. Food and Drug Administration of the New Drug Application with respect to the opioid overdose reversal treatment; and (2) the commencement of two trials on or subsequent to October 23, 2015; and (ii) the Expiration Date.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Pollack Kevin
445 PARK AVENUE, 9TH FLOOR
NEW YORK, NY 10022 		X X Chief Financial Officer

Signatures
/s/ Kevin Pollack 10/29/2015
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Opiant Pharmaceuticals Charts.
Opiant Pharmaceuticals (NASDAQ:OPNT)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Opiant Pharmaceuticals Charts.